These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26151231)

  • 1. Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.
    Han S; Zhang FF; Qian HY; Chen LL; Pu JB; Xie X; Chen JZ
    J Med Chem; 2015 Aug; 58(15):5751-69. PubMed ID: 26151231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor Agonists with in Vivo Efficacy in a Mouse Model of Multiple Sclerosis.
    Shi Y; Duan YH; Ji YY; Wang ZL; Wu YR; Gunosewoyo H; Xie XY; Chen JZ; Yang F; Li J; Tang J; Xie X; Yu LF
    J Med Chem; 2017 Aug; 60(16):7067-7083. PubMed ID: 28726401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.
    Han S; Zhang FF; Qian HY; Chen LL; Pu JB; Xie X; Chen JZ
    Eur J Med Chem; 2015 Mar; 93():16-32. PubMed ID: 25644673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of quinolinyl and isoquinolinyl phenyl ketones as novel agonists for the cannabinoid CB2 receptor.
    Reux B; Nevalainen T; Raitio KH; Koskinen AM
    Bioorg Med Chem; 2009 Jul; 17(13):4441-7. PubMed ID: 19477133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis.
    Porter RF; Szczesniak AM; Toguri JT; Gebremeskel S; Johnston B; Lehmann C; Fingerle J; Rothenhäusler B; Perret C; Rogers-Evans M; Kimbara A; Nettekoven M; Guba W; Grether U; Ullmer C; Kelly MEM
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31540271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.
    Stern E; Muccioli GG; Bosier B; Hamtiaux L; Millet R; Poupaert JH; Hénichart JP; Depreux P; Goossens JF; Lambert DM
    J Med Chem; 2007 Nov; 50(22):5471-84. PubMed ID: 17915849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, and SAR Studies of Heteroarylpyrimidines and Heteroaryltriazines as CB
    Qian HY; Wang ZL; Chen LL; Pan YL; Xie XY; Xie X; Chen JZ
    ChemMedChem; 2018 Nov; 13(22):2455-2463. PubMed ID: 30246417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as selective CB(2) cannabinoid receptor ligands: structural investigations around a novel class of full agonists.
    Baraldi PG; Saponaro G; Moorman AR; Romagnoli R; Preti D; Baraldi S; Ruggiero E; Varani K; Targa M; Vincenzi F; Borea PA; Aghazadeh Tabrizi M
    J Med Chem; 2012 Jul; 55(14):6608-23. PubMed ID: 22738271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.
    Manera C; Benetti V; Castelli MP; Cavallini T; Lazzarotti S; Pibiri F; Saccomanni G; Tuccinardi T; Vannacci A; Martinelli A; Ferrarini PL
    J Med Chem; 2006 Oct; 49(20):5947-57. PubMed ID: 17004710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1,2-Dihydro-2-oxopyridine-3-carboxamides: the C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor.
    Lucchesi V; Parkkari T; Savinainen JR; Malfitano AM; Allarà M; Bertini S; Castelli F; Del Carlo S; Laezza C; Ligresti A; Saccomanni G; Bifulco M; Di Marzo V; Macchia M; Manera C
    Eur J Med Chem; 2014 Mar; 74():524-32. PubMed ID: 24518874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
    Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD
    J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis.
    Ribeiro R; Yu F; Wen J; Vana A; Zhang Y
    Neuroscience; 2013 Dec; 254():427-42. PubMed ID: 24036373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Selective Inverse Agonist of the CB
    Martella A; Sijben H; Rufer AC; Grether U; Fingerle J; Ullmer C; Hartung T; IJzerman AP; van der Stelt M; Heitman LH
    Mol Pharmacol; 2017 Oct; 92(4):389-400. PubMed ID: 28747489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor.
    Geldenhuys WJ; Kuzenko SR; Simmons MA
    J Med Chem; 2010 Nov; 53(22):8080-8. PubMed ID: 21047106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R).
    Graziano G; Delre P; Carofiglio F; Brea J; Ligresti A; Kostrzewa M; Riganti C; Gioè-Gallo C; Majellaro M; Nicolotti O; Colabufo NA; Abate C; Loza MI; Sotelo E; Mangiatordi GF; Contino M; Stefanachi A; Leonetti F
    Eur J Med Chem; 2023 Feb; 248():115109. PubMed ID: 36657299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.
    Chen JZ; Han XW; Liu Q; Makriyannis A; Wang J; Xie XQ
    J Med Chem; 2006 Jan; 49(2):625-36. PubMed ID: 16420048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
    Muccioli GG; Wouters J; Charlier C; Scriba GK; Pizza T; Di Pace P; De Martino P; Poppitz W; Poupaert JH; Lambert DM
    J Med Chem; 2006 Feb; 49(3):872-82. PubMed ID: 16451053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
    Brizzi A; Aiello F; Marini P; Cascio MG; Corelli F; Brizzi V; De Petrocellis L; Ligresti A; Luongo L; Lamponi S; Maione S; Pertwee RG; Di Marzo V
    Bioorg Med Chem; 2014 Sep; 22(17):4770-83. PubMed ID: 25065940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
    De Freitas GB; da Silva LL; Romeiro NC; Fraga CA
    Eur J Med Chem; 2009 Jun; 44(6):2482-96. PubMed ID: 19249138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
    Showalter VM; Compton DR; Martin BR; Abood ME
    J Pharmacol Exp Ther; 1996 Sep; 278(3):989-99. PubMed ID: 8819477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.